Insulin-like Growth Factor I and Insulin and Their Abuse in Sport

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 1, 2010, Pages 33-43

  Erotokritou Mulligan, Ioulietta ^a   Holt, Richard I G ^a  

^a NONE

Author keywords

Doping in sport; Insulin; Insulin like growth factor I

Indexed keywords

ERYTHROPOIETIN; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; INSULIN; INSULIN LISPRO; MECASERMIN RINFABATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ATHLETIC PERFORMANCE; BLOOD ANALYSIS; BODY COMPOSITION; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DOPING; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ELECTROPHORESIS; ENDOCRINE DISEASE; ENDURANCE; EXERCISE TOLERANCE; FLUID RETENTION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GROWTH DISORDER; GROWTH HORMONE INSENSITIVITY SYNDROME; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HEPATOMEGALY; HUMAN; HYPOGLYCEMIA; IMMUNOASSAY; INJECTION SITE ERYTHEMA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY HYPERTROPHY; LIPID METABOLISM; LIPOHYPERTROPHY; LIVER DYSFUNCTION; MASS SPECTROMETRY; MUSCLE MASS; MUSCLE TRAINING; MYALGIA; MYOTONIC DYSTROPHY; NEOPLASM; NONHUMAN; PAIN; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT; THYROID DISEASE; TONSIL DISEASE; URINALYSIS; WEIGHT GAIN;

ANABOLIC AGENTS; ANIMALS; ATHLETIC PERFORMANCE; DOPING IN SPORTS; GLUCOSE; HUMANS; IMMUNOASSAY; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOLYSIS; PROTEIN BIOSYNTHESIS; RECOMBINANT PROTEINS;

EID: 74049106173     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.10.003     Document Type: Review

References (38)

1. Holt R.I., and Sonksen P.H. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol 154 3 (2008) 542-556
2. World Anti-Doping Agency. The World Anti-Doping Code-the 2009 prohibited list International Standard. Available at:. http://www.wada-ama.org/rtecontent/document/2009_Prohibited_List_ENG_Final_20_Sept_08.pdf Accessed July 29, 2009
3. Moller N., and Jorgensen J.O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30 2 (2009) 152-177
4. Norman P. Mecasermin tercica. Curr Opin Investig Drugs 7 4 (2006) 371-380
5. Kemp S.F. Mecasermin rinfabate. Drugs Today (Barc) 43 3 (2007) 149-155
6. Dawson R.T., and Harrison M.W. Use of insulin as an anabolic agent. Br J Sports Med 31 3 (1997) 259
7. Sonksen P.H. Insulin, growth hormone and sport. J Endocrinol 170 1 (2001) 13-25
8. Rinderknecht E., and Humbel R.E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253 8 (1978) 2769-2776
9. Toogood A.A. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm Res 60 Suppl 1 (2003) 105-111
10. Guler H.P., Zapf J., Schmid C., et al. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 121 6 (1989) 753-758
11. Grahnen A., Kastrup K., Heinrich U., et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 82 Suppl 391 (1993) 9-13
12. Houssay B.A., and Biasotti A. La diabetes pancreatica de los perros hipofiseoprivos. Rev Soc Argent Biol 6 (1930) 251-296
13. Salomon F., Cuneo R.C., Hesp R., et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321 26 (1989) 1797-1803
14. Salmon Jr. W.D., and Daughaday W.H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49 6 (1957) 825-836
15. Sjogren K., Liu J.L., Blad K., et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96 12 (1999) 7088-7092
16. Yakar S., Liu J.L., Stannard B., et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96 13 (1999) 7324-7329
17. Russell Jones D.L., Umpleby A.M., Hennessy T.R., et al. Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Phys 267 (1994) 591-598
18. Fryburg D.A. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Phys 267 (1994) 331-336
19. Musaro A., McCullagh K., Paul A., et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27 2 (2001) 195-200
20. Clemmons D.R., Smith-Banks A., and Underwood L.E. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 75 1 (1992) 234-238
21. Laron Z. The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 84 12 (1999) 4397-4404
22. Holt R.I., Simpson H.L., and Sonksen P.H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 20 1 (2003) 3-15
23. Sjogren K., Wallenius K., Liu J.L., et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 50 7 (2001) 1539-1545
24. Jacob R., Barrett E., Plewe G., et al. Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. Comparison with insulin. J Clin Invest 83 5 (1989) 1717-1723
25. Zenobi P.D., Graf S., Ursprung H., et al. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 89 6 (1992) 1908-1913
26. Russell Jones D.L., Bates A.T., Umpleby A.M., et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism, and the cardiovascular system in normal human volunteers. Eur J Clin Invest 25 6 (1995) 403-411
27. Mauras N., O'Brien K.O., Welch S., et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 85 4 (2000) 1686-1694
28. Williams R.M., McDonald A., O'Savage M., et al. Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. Expert Opin Drug Metab Toxicol 4 3 (2008) 311-324
29. Chernausek S.D., Backeljauw P.F., Frane J., et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 92 3 (2007) 902-910
30. Colao A., Marzullo P., Di Somma C., et al. Growth hormone and the heart. Clin Endocrinol 54 2 (2001) 137-154
31. Wu Y., Yakar S., Zhao L., et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62 4 (2002) 1030-1035
32. Nam R.K., Trachtenberg J., Jewett M.A., et al. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14 5 (2005) 1270-1273
33. Giovannucci E., Pollak M.N., Platz E.A., et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9 4 (2000) 345-349
34. Catlin D.H., Breidbach A., Elliott S., et al. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48 11 (2002) 2057-2059
35. Kasukawa Y., Miyakoshi N., and Mohan S. The anabolic effects of GH/IGF system on bone. Curr Pharm Des 10 21 (2004) 2577-2592
36. Guha N., Sonksen P.H., and Holt R.I. IGF-I abuse in sport: Current knowledge and future prospects for detection. Growth Horm IGF Res 19 4 (2009) 408-411
37. Bredehoft M., Schanzer W., and Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 22 4 (2008) 477-485
38. Thevis M., Lohmann W., Schrader Y., et al. Use of an electrochemically synthesised metabolite of a selective androgen receptor modulator for mass spectrometry-based sports drug testing. Eur J Mass Spectrom 14 3 (2008) 163-170